icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
Efficacy and Safety of Glecaprevir/Pibrentasvir in
Renally-Impaired Patients With Chronic HCV Genotype 1-6 Infection

  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Marcello Persico1, Robert Flisiak2, Manal Abunimeh3, Meghan Sise4, Jun Yong Park5, Marwan Kaskas6, Annett e Bruchfeld7, Marcus-Alexander Worns8, Andrea Aglitti 1, Philippe J Zamor9, Zhenyi Xue3, Janean Rullman3, Ariel Porcalla3, Eric Cohen3, Roger Trinh3, Eric Lawitz10 1Internal Medicine and Hepatology Unit, University of Salerno, Italy; 2Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Poland; 3AbbVie Inc., North Chicago, Illinois, United States; 4Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, United States; 5Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; 6Northwest Louisiana Nephrology, Shreveport, Louisiana, United States; 7Department of Renal Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; 8Department of Internal Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, 55101 Mainz, Germany; 9Carolinas Medical Center, Charlotte, North Carolina, United States; 10The Texas Liver Insti tute, University of Texas Health San Antonio, San Antonio, Texas, United States